<DOC>
	<DOCNO>NCT02510794</DOCNO>
	<brief_summary>This Phase II clinical study evaluate efficacy , safety pharmacokinetics three different formulation ranibizumab deliver via Ranibizumab Port Delivery System ( RPDS ) implant compare standard care ( SOC ) intravitreal ( ITV ) injection ranibizumab , participant subfoveal neovascular age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Study Efficacy Safety Ranibizumab Port Delivery System Sustained Delivery Ranibizumab Participants With Subfoveal Neovascular Age-Related Macular Degeneration ( LADDER )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age 50 year Newly diagnose wet AMD within 6 month screen visit Participant must receive least 2 prior antiVEGF injection . The recent antiVEGF injection must ranibizumab must occur least 7 day prior screen visit Participant may receive 6 ITV antiVascular Endothelial Growth factor ( VEGF ) injection prior screen visit Demonstrated response prior SOC ITV antiVEGF treatment Best Corrected Visual Acuity ( BCVA ) use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart 20/2520/200 Snellen equivalent screen visit Willingness ability provide sign informed consent Treatment ITV antiVEGF agent ranibizumab within 1 month prior randomization visit either eye Study eye treatment ITV antiVEGF agent ranibizumab within 1 month prior randomization visit History laser photocoagulation , VisudyneÂ® , ITV corticosteroid injection , vitrectomy surgery , submacular surgery , device implantation , surgical intervention AMD study eye Prior participation clinical trial involve antiangiogenic drug , ranibizumab , either eye within 2 month randomization visit Subretinal hemorrhage study eye involve center fovea Subfoveal fibrosis , atrophy study eye choroidal neovascularization ( CNV ) either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Uncontrolled ocular hypertension glaucoma study eye Uncontrolled blood pressure Uncontrolled atrial fibrillation within 3 month inform consent History myocardial infarction stroke within last 3 month prior inform consent History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use ranibizumab placement Implant , might affect interpretation result study render participant high risk treatment complication Use oral corticosteroid Current treatment active systemic infection Use anticoagulant , antiplatelets ( aspirin ) , medication know exert similar effect Active malignancy within 12 month randomization History allergy fluorescein Previous participation nonocular ( systemic ) disease study investigational drug within 1 month precede informed consent ( exclude vitamin mineral )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>